Rational biomarker development for the early and minimally invasive monitoring of AML.

ABSTRACT: Recurrent disease remains the principal cause for treatment failure in AML across age groups. Reliable biomarkers of AML relapse risk and disease burden have been problematic, as symptoms appear late and current monitoring relies on invasive and cost-ineffective serial BM surveillance. In this report we discover a set of unique micro-RNA that circulate in AML-derived vesicles in the peripheral blood ahead of the general dissemination of leukemic blasts and symptomatic bone marrow failure. Next-generation sequencing of EV-contained small RNA in 12 AML patients and 12 controls allowed us to identify a panel of differentially incorporated miRNA. Proof-of-concept studies using a murine model and patient-derived xenografts demonstrate the feasibility of developing miR-1246, as a potential minimally invasive AML biomarker.

SUBMITTER: Abdelhamed S 

PROVIDER: S-EPMC8579272 | biostudies-literature |

REPOSITORIES: biostudies-literature